This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).
Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
Merck (MRK) to Supply Coronavirus Treatment to U.S. Government
by Zacks Equity Research
Merck (MRK) inks an agreement with the Government of United States for supplying MK-7110, being developed for treating patients with serious COVID-19, if approved.
Ocular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up
by Zacks Equity Research
The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021. Shares rise.
Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.
Roche's (RHHBY) DME Drug Meets Primary Endpoint in Studies
by Zacks Equity Research
Roche's (RHHBY) investigational bispecific antibody, faricimab, meets the primary endpoints in two late-stage studies for diabetic acular edema.
Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis' (NVS) late-stage study on ruxolitinib in COVID-19 patients did not meet its primary endpoint.
The Zacks Analyst Blog Highlights: Oracle, Adobe, Costco, AutoZone, Regeneron Pharmaceuticals and Bank of New York Mellon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Adobe, Costco, AutoZone, Regeneron Pharmaceuticals and Bank of New York Mellon
Regeneron (REGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $479.77 in the latest trading session, marking a +0.16% move from the prior day.
Q4 Earnings Season Update and Analyst Reports for BHP, Starbucks & Snap
by Sheraz Mian
We have provided an update on the Q4 earnings season in today's note, in addition to featuring new research reports on 16 major stocks, including BHP (BHP), Starbucks (SBUX) and Snap (SNAP).
Glaxo's (GSK) Nucala Filing for Nasal Polyps Accepted by FDA
by Zacks Equity Research
The FDA accepts Glaxo's (GSK) regulatory filing for Nucala to treat patients with chronic rhinosinusitis with nasal polyps. The drug is already approved for three other indications.
Regeneron (REGN) Posts Upbeat Data on Myeloma Candidate at ASH
by Zacks Equity Research
Regeneron (REGN) releases encouraging data from early-stage study on REGN5458 at the ASH 2020.
Regeneron (REGN) Down 16.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US
by Zacks Equity Research
With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).
5 Stocks in Dow ETF That Powered the Best Month Since 1987
by Sweta Killa
Amid rising COVID-19 cases, the Dow Jones wrapped up its best month in more than 30 years after hitting the major milestone of 30,000 for the first time last week.
Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion
by Zacks Equity Research
Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.
RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US
by Zacks Equity Research
RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.
Energy on Track for Its Best Month Ever: 5 ETF, Stock Winners
by Sweta Killa
The S&P 500 Energy Index is on track for the best month ever, gaining nearly 40%.
Is Regeneron Pharmaceuticals (REGN) a Worthy Stock Now?
by Zacks Equity Research
Let's see if Regeneron Pharmaceuticals (REGN) stock is a good choice for value-oriented investors right now from multiple angles.
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19
by Zacks Equity Research
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.
Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.
Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA
by Zacks Equity Research
Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.
Spread of Top-Ranked Value ETFs to Bet on Vaccine Optimism
by Sweta Killa
The potential arrival of a coronavirus vaccine will end the pandemic crisis, keeping the economy recovery intact, and will boost consumer spending and in turn lift value stocks.